Zhicheng C. Yao - Publications

Metabolic Dysfunction-associated Steatotic Liver Disease Diminishes the Efficacy of miR-125b-5p-engineered MSC Therapy for Hepatocellular Carcinoma via HK2 Upregulation: A Multimodal Theranostic Study.

Journal: Journal of clinical and translational hepatology

Published: December 31, 2025

Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis.

Journal: PeerJ

Published: September 02, 2025

Icariin regulates osteogenic/adipogenic differentiation of bone marrow mesenchymal stem cells in postmenopausal osteoporosis, potentially via the AMPK-mTOR-autophagy pathway.

Journal: Toxicology and applied pharmacology

Published: September 01, 2025

Dynamics changes of spleen volume predict survival outcomes in unresectable hepatocellular carcinoma treated with tislelizumab plus lenvatinib.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 20, 2025

β-Sitosterol Suppresses Osteoclastogenesis and Alleviates Bone Loss by Targeting Tmed10 to Inhibit RANKL-Induced Hedgehog/MAPK Signaling and ROS.

Journal: Phytotherapy research : PTR

Published: August 10, 2025

Revalidation of Manis aurita based on integrative genomic and morphological evidence.

Journal: Communications biology

Published: July 25, 2025

Cyasterone Improves Mitochondrial Function and Protects against Knee Osteoarthritis by Activating PPARγ.

Journal: Current medicinal chemistry

Published: June 24, 2025

Cardiovascular Fitness and Potential Risk of Work-Related Injuries in Manual Therapy Students: A Cross-Sectional Study.

Journal: Cureus

Published: May 13, 2025

Exosome-derived hsa_circ_0007132 promotes lenvatinib resistance by inhibiting the ubiquitin-mediated degradation of NONO.

Journal: Non-coding RNA research

Published: February 17, 2025

Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: January 22, 2025

Comparative analysis of hepatectomy for HCC with PVTT: Insights from a 30-year single-center experience: Hepatectomy for HCC with PVTT.

Journal: Surgical oncology

Published: December 20, 2024

CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: September 01, 2024